| Title |
ATM Mutations in Cancer: Therapeutic Implications
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, August 2016
|
| DOI | 10.1158/1535-7163.mct-15-0945 |
| Pubmed ID | |
| Authors |
Michael Choi, Thomas Kipps, Razelle Kurzrock |
| Abstract |
Activation of checkpoint arrest and homologous DNA repair are necessary for maintenance of genomic integrity during DNA replication. Germ-line mutations of the ataxia telangiectasia mutated (ATM) gene result in the well-characterized ataxia telangiectasia syndrome, which manifests with an increased cancer predisposition, including a 20% to 30% lifetime risk of lymphoid, gastric, breast, central nervous system, skin, and other cancers. Somatic ATM mutations or deletions are commonly found in lymphoid malignancies, as well as a variety of solid tumors. Such mutations may result in chemotherapy resistance and adverse prognosis, but may also be exploited by existing or emerging targeted therapies that produce synthetic lethal states. Mol Cancer Ther; 15(8); 1-11. ©2016 AACR. |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 29% |
| United States | 4 | 24% |
| Italy | 1 | 6% |
| Brazil | 1 | 6% |
| Canada | 1 | 6% |
| Unknown | 5 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 53% |
| Scientists | 5 | 29% |
| Practitioners (doctors, other healthcare professionals) | 3 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 463 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | <1% |
| Unknown | 462 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 69 | 15% |
| Student > Ph. D. Student | 68 | 15% |
| Student > Bachelor | 68 | 15% |
| Student > Master | 46 | 10% |
| Other | 26 | 6% |
| Other | 60 | 13% |
| Unknown | 126 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 149 | 32% |
| Medicine and Dentistry | 76 | 16% |
| Agricultural and Biological Sciences | 33 | 7% |
| Immunology and Microbiology | 15 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 3% |
| Other | 36 | 8% |
| Unknown | 142 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2023.
All research outputs
#1,269,559
of 23,485,204 outputs
Outputs from Molecular Cancer Therapeutics
#125
of 3,914 outputs
Outputs of similar age
#25,836
of 369,820 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#3
of 64 outputs
Altmetric has tracked 23,485,204 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,914 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 369,820 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.